Ovarian Cancer Subtypes May Predict Response to Bevacizumab

1,341 views · Published 23 June 2014 · 1:59 · Indexed 18 October 2026

Channel: Mayo Clinic · 2014 · Science & Technology

Watch on YouTube

Sean Dowdy, M.D., a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. For more information 

More from this channel